Australian anti-cancer drug picked as one of the world’s top 10 most promising new drug products in 2011
"We are excited with the promise MDX-1097 has demonstrated to date in patients with multiple myeloma, and pleased that industry experts have recognized the potential of this new drug candidate to attract partners to accelerate its development," said IST Chief Executive Officer Dr Calum McKinlay.
In June 2011, MDX-1097 received orphan drug designation from US health regulators, giving the company and its potential licensing partners help with the regulatory approval process and marketing exclusivity in the US for a number of years. IST also recently announced the expansion of its Phase IIa clinical trial in Australia following encouraging responses from the first dosed patients and positive safety data.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.